In this ongoing trial, the authors randomly assigned 44,165 participants aged 16 or older and 2,264 participants aged 12-15 to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo.

EAN was able to welcome 46 participants from 15 countries - Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Portugal, Romania, Russia, Spain, Tunisia, Turkey and Ukraine - to Loutraki.

The objective of this study was to explore the perceived impact of confinement in patients with Parkinson's disease and document the effects of gender and living environment.

This study aimed to explore the associations of objective cognitive performances and psychological distress with cognitive complaints in COVID-19 survivors.

The objective of this study was to determine clinical characteristics and outcomes in hospitalised PD individuals infected with COVID-19.

The objective of this study was to determine whether previously identified risk factors for 30-day mortality in Dutch NH residents with COVID-19 are unique to COVID-19.

In this review, the authors summarize possible mechanisms by which infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, may cause AD in elderly COVID-19 patients and describe preventive measures to mitigate risk.

The European Federation of Neurological Associations, in partnership with the NeuroCOVID-19 taskforce of the European Academy of Neurology, has investigated the impact of the first wave of the COVID-19 pandemic on patients with neurological diseases, as well as the hopes and fears of these patients about the post-pandemic phase.

The aims of this study were to analyze the characteristics and outcomes of patients with stroke admitted during the second COVID-19 wave and to evaluate the differences in the stroke care provision compared with the first wave.

The aim of this study was to evaluate whether mortality of patients with CVST-VITT has decreased over time.

In this article the authors review neurological conditions seen in the context of prior vaccinations and the current data to date on select COVID-19 vaccines.

This study describes the perspectives and experiences of community neurologists providing care for patients with neurodegenerative illnesses during the COVID-19 pandemic.

In this study the authors conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 d of respiratory symptom onset (NCT04348656).

In this article the authors investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis (MS) on anti-CD20 antibody monotherapy (n = 20) compared with healthy controls (n = 10) after BNT162b2 or mRNA-1273 mRNA vaccination.

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for treatment are still very limited.